Evidence-based options for treatment-resistant adult bipolar disorder patients

Bipolar Disorders

Volumn 14, Issue 6, 2012, Pages 573-584

  Poon, Shi Hui ^a   Sim, Kang ^a   Sum, Min Yi ^a   Kuswanto, Carissa Nadia ^a   Baldessarini, Ross J ^b,c  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bipolar disorder; Depression; Mania; Polytherapy; Treatment resistance

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DILTIAZEM; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; LITHIUM CARBONATE; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PRAMIPEXOLE; QUETIAPINE; THYROID HORMONE; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADULT; BEHAVIOR THERAPY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; BRAIN DEPTH STIMULATION; DEPRESSION; DYSPHORIA; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MANIA; PATIENT CARE; PHOTOTHERAPY; PRIORITY JOURNAL; PSYCHOEDUCATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SLEEP DEPRIVATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESISTANT BIPOLAR DEPRESSION; TREATMENT RESISTANT BIPOLAR DISORDER; TREATMENT RESISTANT BIPOLAR MANIA; TREATMENT RESISTANT DEPRESSION; TREATMENT RESISTANT MANIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; COMBINED MODALITY THERAPY; DEEP BRAIN STIMULATION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOPAMINE AGONISTS; ELECTROCONVULSIVE THERAPY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; PHOTOTHERAPY; THYROID HORMONES; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84865766987     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.01042.x     Document Type: Review

References (96)

1. Goodwin RK, Jamison KR. Manic-Depressive Illness, 2nd edn. New York: Oxford University Press, 2007.
2. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: WHO Press, 2008. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. [accessed May 19, 2010].
3. Baldessarini RJ, Tondo L, Vázquez GH et al. International study of functional and symptomatic outcome versus onset-age in 1437 bipolar-I disorder patients. World Psychiatry 2012; 11: 40-46.
4. Tondo L, Lepri B, Cruz N, Baldessarini RJ. Age at onset in 3014 Sardinian bipolar and major depressive disorder patients. Acta Psychiatr Scand 2010; 121: 446-452.
5. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Co-morbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
6. Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002; 359: 241-247.
7. Baldessarini RJ, Salvatore P, Khalsa HM et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord 2010; 12: 264-270.
8. Judd LL, Akiskal HS, Schettler PJ et al. Long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
9. Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the STEP-BP program. Am J Psychiatry 2006; 163: 217-224.
10. Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord 2010; 12: 364-375.
11. Osby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844-850.
12. Tondo L, Lepri B, Baldessarini RJ. Risks of suicidal ideation, attempts and suicides among 2826 men and women with types I and II bipolar, and recurrent major depressive disorders. Acta Psychiatr Scand 2007; 116: 419-428.
13. Dell'Osso B, Mundo E, D'Urso N et al. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord 2009; 11: 76-81.
14. Erfurth A, Michael N, Stadtland C, Arolt V. Bupropion as Add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology 2002; 45 (Suppl. 1): 33-36.
15. González-Isasi A, Echeburúa E, Mosquera F, Ibáñez B, Aizpuru F, González-Pinto A. Long-term efficacy of psychological intervention program for patients with refractory bipolar disorder: pilot study. Psychiatry Res 2010; 176: 161-165.
16. Pacchiarotti I, Mazzarini L, Colom F et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120: 429-440.
17. Benedetti F, Barbini B, Fulgosi MC et al. Combined total sleep-deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. J Clin Psychiatry 2005; 66: 1535-1540.
18. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood-stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-566.
19. Baldassano CF, Hosey A, Coello J. Bipolar depression: an evidence-based approach. Curr Psychiatry Rep 2011; 13: 483-487.
20. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-236.
21. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006; 11: 227-240.
22. Benedetti A, Di Paolo A, Lastella M et al. Augmentation of clozapine with aripiprazole in severe psychotic and schizoaffective disorders: pilot study. Clin Pract Epidemiol Ment Health 2010; 6: 30-35.
23. Diazgranados N, Ibrahim L, Brutsche NE et al. Randomized add-on trial of an N-methy-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802.
24. Sharma V, Khan M, Corpse C. Role of lamotrigine in the management of treatment-resistant bipolar II depression: chart review. J Affect Disord 2008; 111: 100-105.
25. Baldessarini RJ, Tarazi FI. Drugs for psychosis and mania. In: Brunton LL, Lazo JS, Parker KL eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill Press, 2005: 461-500.
26. Tohen M, Frank E, Bowden CL et al. The International Society for Bipolar Disorders (ISBD) task force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009; 11: 453-473.
27. Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003; 160: 2099-2107.
28. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011; 36: 375-389.
29. Keck PE Jr, McElroy SL. Definition, evaluation, and management of treatment refractory mania. Psychopharmacol Bull 2001; 35: 130-148.
30. Sackeim HA. Definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62 (Suppl. 16): 10-17.
31. Baldessarini RJ. Chemotherapy in Psychiatry, 3rd edn. New York: Springer-Verlag, 2012.
32. Baldessarini RJ, Henk HJ, Sklar AR, Chang J, Leahy LF. Psychotropic medications for bipolar disorder patients in the United States: polytherapy and adherence. Psychiatr Serv 2008; 59: 1175-1183.
33. Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder. Bipolar Disord 2009; 11: 225-255.
34. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol 2010; 25: 179-186.
35. Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-764.
36. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-1169.
37. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64: 451-458.
38. Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67: 461-467.
39. Banov MD, Zarate CA Jr, Tohen M et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295-300.
40. Chen J, Muzina DJ, Kemp DE et al. Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study. Hum Psychopharmacol 2011; 26: 588-595.
41. Keck PE Jr, Marcus R, Tourkodimitris S et al. Placebo-controlled, double-blind study of efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-1658.
42. Sachs GS, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536-546.
43. Keck PE Jr, Calabrese JR, McQuade RD et al. Randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-637.
44. Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 2011; 8: e1000434.
45. Janowsky DS, el-Yousef MK, Davis JM, Hubbard B, Sekerke HJ. Cholinergic reversal of manic symptoms. Lancet 1972; 1: 1236-1237.
46. Burt T, Sachs GS, Demopulos C. Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 1999; 45: 959-964.
47. Evins AE, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord 2006; 8: 75-80.
48. Benazzi F. Mania associated with donepezil. Int J Geriatr Psychiatry 1998; 13: 814-815.
49. Benazzi F, Rossi E. Mania and donepezil. Can J Psychiatry 1999; 44: 506-507.
50. Nierenberg AA, Ostacher MJ, Calabrese JR et al. Treatment-resistant bipolar depression: STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210-216.
51. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614.
52. Ahn YM, Nam JY, Culver JL, Marsh WK, Bonner JC, Ketter TA. Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression. Ann Clin Psychiatry 2011; 23: 17-24.
53. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006; 18: 169-172.
54. Kemp DE, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Progr Neuropsychopharmacol Biol Psychiatry 2007; 31: 574-577.
55. Cleare AJ, McGregor A, O'Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol 1995; 43: 713-719.
56. Lasser RA, Baldessarini RJ. Thyroid hormones in depressive disorders: reappraisal of clinical utility. Harv Rev Psychiatry 1997; 4: 291-305.
57. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70 (Suppl. 6): 16-25.
58. Baumgartner A. Thyroxine and the treatment of affective disorders: overview of results of basic and clinical research. Int J Neuropsychopharmacol 2000; 3: 149-165.
59. Kelly T, Lieberman DZ. Use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder-NOS. J Affect Disord 2009; 116: 222-226.
60. Bauer M, Fairbanks L, Berghöfer A et al. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. J Affect Disord 2004; 83: 183-190.
61. Gyulai L, Bauer M, Garcia-Espana F et al. Bone mineral density in pre- and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001; 66: 185-191.
62. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010; 121: 404-414.
63. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 2010; 18: 293-303.
64. Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G. Role of pramipexole in the management of Parkinson's disease. CNS Drugs 2010; 24: 829-841.
65. Inoue T, Kitaichi Y, Masui T et al. Pramipexole for stage 2 treatment-resistant major depression: an open study. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1446-1449.
66. Mah L, Zarate CA Jr, Nugent AC, Singh JB, Manji HK, Drevets WC. Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int J Neuropsychopharmacol 2011; 14: 545-551.
67. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72: 356-366.
68. Zarate CA, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60.
69. Medda P, Perugi G, Zanello S, Ciuffa M, Rizzato S, Cassano GB. Comparative response to electroconvulsive therapy in medication-resistant bipolar I patients with depression and mixed state. J ECT 2010; 26: 82-86.
70. Macedo-Soares MB, Morena RA, Rigonatti SP, Lafer B. Efficacy of electroconvulsive therapy in treatment-resistant bipolar disorder: a case series. J ECT 2005; 21: 31-34.
71. Höppner J, Schulz M, Irmisch G, Mau R, Schläfke D, Richter J. Antidepressant efficacy of two different rTMS procedures. High frequency over left versus low frequency over right prefrontal cortex compared with sham stimulation. Eur Arch Psychiatry Clin Neurosci 2003; 253: 103-109.
72. Kauffmann CD, Cheema MA, Miller BE. Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: double-blind, placebo-controlled study. Depress Anxiety 2004; 19: 59-62.
73. Holtzheimer PE, Kelley ME, Gross RE et al. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry 2012; 69: 150-158.
74. Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993; 54: 380-384.
75. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91.
76. Hennen J, Baldessarini RJ. Reduced suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Res 2005; 73: 139-145.
77. Vieta E, Reinares M, Corbella B et al. Olanzapine a long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001; 21: 469-473.
78. Levy NA, Janicak PG. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord 2000; 2: 108-119.
79. Vasudev K, Macritchie K, Geddes J, Watson S, Young A. Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2006; 25: CD003384.
80. Chengappa RKN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67: 1698-1706.
81. Vieta E, Torrent C, Garcia-Ribas G et al. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 2002; 22: 431-435.
82. Casamassima F, Hay AC, Benedetti A, Lattanzi L, Cassano GB, Perlis RH. L-type calcium channels and psychiatric disorders: brief review. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1373-1390.
83. Silverstone PH, Birkett L. Diltiazem as augmentation therapy in patients with treatment-resistant bipolar disorder: retrospective study. J Psychiatry Neurosci 2000; 25: 276-280.
84. Koukopoulos A, Reginaldi D, Serra G, Koukopoulos A, Sani G, Serra G. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord 2010; 12: 348-349.
85. Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord 2012; 136: 163-166.
86. Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry 2000; 8: 126-140.
87. Lauder SD, Berk M, Castle DJ, Dodd S, Berk L. The role of psychotherapy in bipolar disorder. Med J Austral 2010; 193 (Suppl. 4): S31-S35.
88. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden C. Bipolar depression: overview and commentary. Harv Rev Psychiatry 2010; 18: 143-157.
89. Colom F, Vieta E, Daban C, Pacchiarotti I, Sánchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006; 93: 13-17.
90. Gutiérrez-Rojas L, Gurpegui M, Ayuso-Mateos JL, Gutiérrez-Ariza JA, Ruiz-Veguilla M, Jurado D. Quality of life in bipolar disorder patients: a comparison with a general population sample. Bipolar Disord 2008; 10: 625-634.
91. Martinez-Aran A, Vieta E, Torrent C et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord 2007; 9: 103-113.
92. Malhi GS, Ivanovski B, Hadzi-Pavlovic D, Mitchell PB, Vieta E, Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007; 9: 114-125.
93. Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY. Clozapine in treatment-refractory mood disorders. J Clin Psychiatry 1994; 55 (Suppl. B): 91-93.
94. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64: 442-455.
95. Miklowitz DJ. Functional impairment, stress, and psychosocial intervention in bipolar disorder. Curr Psychiatry Rep 2011; 13: 504-512.
96. Schöttle D, Huber CG, Bock T, Meyer TD. Psychotherapy for bipolar disorder: review of the most recent studies. Curr Opin Psychiatry 2011; 24: 549-555.